Gliclazide | 格列齐特 | MedChemExpress (MCE)

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Gliclazide

CAS No. : 21187-98-4

MCE 国际站：Gliclazide

产品活性：Gliclazide (S1702) 是全细胞的 β 细胞 ATP 敏感型钾流 (potassium currents) 阻断剂，IC₅₀ 为 184 nM，用作降糖药。

研究领域：Membrane Transporter/Ion Channel

作用靶点：Potassium Channel

In Vitro: Gliclazide (S1702) further characterize its mechanism of hypoglycemic effect: the observed improvements in insulin sensitivity and in GLUT4 translocation indicate that gliclazide counters the hydrogen peroxide-induced insulin resistance in 3T3L1 adipocytes and also would further augment the hypoglycemic effect of this drug as insulinotropic sulfonylurea.
Gliclazide blocked whole-cell beta-cell KATP currents with an IC₅₀ of 184 +/- 30 nmol/l (n=6-10) but was much less effective in cardiac and smooth muscle (IC₅₀s of 19.5 +/- 5.4 micromol/l (n=6-12) and 37.9 +/- 1.0 micromol/l (n=5-10), respectively). In all three tissues, the action of the drug on whole-cell KATP currents was rapidly reversible. In inside-out patches on beta-cells, gliclazide (1 micromol/l) produced a maximum of 66 +/- 13 % inhibition (n=5), compared with more than 98 % block in the whole-cell configuration. Gliclazide is a high-potency sulphonylurea which shows specificity for the pancreatic beta-cell KATP channel over heart and smooth muscle. In this respect, it differs from glibenclamide.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Anti-diabetic Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer's Disease Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Potassium Channel Compound Library  |  Human Metabolite Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Ion Channel Compound Library  |  Nigericin sodium salt  |  Yoda 1  |  BAPTA-AM  |  Minocycline hydrochloride  |  Branaplam  |  Rosuvastatin Calcium  |  SCH-23390 hydrochloride  |  Glibenclamide  |  Quinidine (15% dihydroquinidine)  |  Tetrandrine  |  Carbamazepine  |  Amiodarone hydrochloride  |  E-4031  |  DCPIB  |  Minoxidil  |  20(S)-Ginsenoside Rg3  |  Tannic acid  |  Guanosine 5'-diphosphate disodium salt  |  TRAM-34  |  Quinine  |  (±)-Naringenin  |  SKF-96365 hydrochloride  |  Terfenadine  |  Astemizole  |  PAP-1  |  Flufenamic acid  |  Mefloquine hydrochloride  |  Ifenprodil tartrate  |  4-Aminopyridine  |  GW9508

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。